Show Summary Details
Page of

Haemopoietic diseases: leukaemias and myelomas 

Haemopoietic diseases: leukaemias and myelomas
Chapter:
Haemopoietic diseases: leukaemias and myelomas
Author(s):

Roberto Mina

, Alessandra Larocca

, and Antonio Palumbo

DOI:
10.1093/med/9780198701590.003.0094
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 August 2019

The demographic revolution driven by the ageing of the general population is rapidly changing the therapeutic landscape in the onco-haematological setting. Acute and chronic leukaemias and myeloma are typical disorders of older people, and their incidence is expected to rise in the near future. The introduction of new targeted drugs has led to a survival improvement, which is still significantly inferior in elderly patients as compared with younger ones. The current approach to older patients, based on chronological age and performance status, is no longer sufficient to fully characterize patients, whereas comprehensive geriatric assessment (CGA) is a better tool to make a thorough evaluation (physical and cognitive) and to tailor treatment according to patients’ fitness. Since there is evolving consensus about the optimal tools for a geriatric evaluation in the haematological setting, studies aimed at validating CGA are necessary to stratify patients and guide physicians in the choice of treatment.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.